ReviewCurrent treatment options in oncology2019
Controversies in the Therapy of Low-Grade Gliomas.
Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Left-hemisphere glioma drives systematic patterns of contralesional functional connectivity.Brain communications · 2025Article
- Glutathione metabolism-related gene signature predicts prognosis and treatment response in low-grade glioma.Aging · 2024Article
- Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI.European radiology · 2024Article
- Risk prediction and treatment assessment in glioma patients using SEER database: a prospective observational study.BMJ open · 2023Observational
- Reasoning and causal inference regarding surgical options for patients with low-grade gliomas using machine learning: A SEER-based study.Cancer medicine · 2023Article
- AnPeerJ · 2023Article
- A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients.Frontiers in immunology · 2023Article
- Risk factors for early progression of diffuse low-grade glioma in adults.Chinese neurosurgical journal · 2022Article
- Neuroplasticity of Glioma Patients: Brain Structure and Topological Network.Frontiers in neurology · 2022Review
- Contralesional Structural Plasticity in Different Molecular Pathologic Subtypes of Insular Glioma.Frontiers in neurology · 2021Article
- Tumor Suppressor microRNA-138 Suppresses Low-Grade Glioma Development and Metastasis via Regulating IGF2BP2.OncoTargets and therapy · 2020Article
- Prognostic value ofNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementIn the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild-type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk-low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.
Indexed as
Identifiers
30874903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.